Abrogation of galectin-4 expression promotes tumorigenesis in colorectal cancer

Seung Won Kim, Ki Cheong Park, Soung Min Jeon, Tak Bum Ohn, Tae Il Kim, Won Ho Kim, Jae Hee Cheon

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Background: Although it has been well established that galectin-4 is selectively expressed by intestinal epithelial cells, the role of galectin-4 in colorectal cancer (CRC) development is, as yet, poorly understood. Here, we aimed to explore the role of galectin-4 in CRC development, both in vitro and in vivo. Methods: Galectin-4 expression was investigated in tissue specimens from patients with adenoma, carcinoma and ulcerative colitis (UC) using immunohistochemistry. Colorectal cancer-derived HT-29 cells, in which galectin-4 expression was knocked down, were established using shRNA. mRNA and protein expression levels of galectin-4 and several downstream cancer-related genes were analyzed using RT-PCR, qPCR array, Western blotting, and immunofluorescence assays. To investigate the effect of galectin-4 expression abrogation on tumorigenesis in vivo, xenograft assays were performed. Results: Immunohistochemistry analyses showed high expression levels of galectin-4 in normal colon mucosa tissues. Conversely, the expression levels of galectin-4 were significantly lower in CRC samples and its precursor lesions with dysplasia or inflammation. We found that shRNA-mediated galectin-4 silencing increases cell proliferation and, concomitantly, activates NF-κB and STAT3 signaling along with IL-6 up-regulation. In addition, we found that shRNA-mediated galectin-4 silencing promotes the expression of NF-κB target genes and other cancer-related genes and, concomitantly, enhances the in vivo growth of xenografts. Conclusions: We show that abrogation of galectin-4 expression promotes cancer cell proliferation and, for the first time, provide evidence that down-regulation of galectin-4 elicits tumor promotion in vitro and in vivo through activation of IL-6/NF-κB/STAT3 signaling.

Original languageEnglish
Pages (from-to)169-178
Number of pages10
JournalCellular Oncology
Volume36
Issue number2
DOIs
Publication statusPublished - 2013 Apr 1

Fingerprint

Galectin 4
Colorectal Neoplasms
Carcinogenesis
Small Interfering RNA
Neoplasm Genes
Heterografts
Interleukin-6
Immunohistochemistry
Cell Proliferation
HT29 Cells

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Oncology
  • Cancer Research

Cite this

Kim, Seung Won ; Park, Ki Cheong ; Jeon, Soung Min ; Ohn, Tak Bum ; Kim, Tae Il ; Kim, Won Ho ; Cheon, Jae Hee. / Abrogation of galectin-4 expression promotes tumorigenesis in colorectal cancer. In: Cellular Oncology. 2013 ; Vol. 36, No. 2. pp. 169-178.
@article{74708ea23c5f4040ad533916b46c60d1,
title = "Abrogation of galectin-4 expression promotes tumorigenesis in colorectal cancer",
abstract = "Background: Although it has been well established that galectin-4 is selectively expressed by intestinal epithelial cells, the role of galectin-4 in colorectal cancer (CRC) development is, as yet, poorly understood. Here, we aimed to explore the role of galectin-4 in CRC development, both in vitro and in vivo. Methods: Galectin-4 expression was investigated in tissue specimens from patients with adenoma, carcinoma and ulcerative colitis (UC) using immunohistochemistry. Colorectal cancer-derived HT-29 cells, in which galectin-4 expression was knocked down, were established using shRNA. mRNA and protein expression levels of galectin-4 and several downstream cancer-related genes were analyzed using RT-PCR, qPCR array, Western blotting, and immunofluorescence assays. To investigate the effect of galectin-4 expression abrogation on tumorigenesis in vivo, xenograft assays were performed. Results: Immunohistochemistry analyses showed high expression levels of galectin-4 in normal colon mucosa tissues. Conversely, the expression levels of galectin-4 were significantly lower in CRC samples and its precursor lesions with dysplasia or inflammation. We found that shRNA-mediated galectin-4 silencing increases cell proliferation and, concomitantly, activates NF-κB and STAT3 signaling along with IL-6 up-regulation. In addition, we found that shRNA-mediated galectin-4 silencing promotes the expression of NF-κB target genes and other cancer-related genes and, concomitantly, enhances the in vivo growth of xenografts. Conclusions: We show that abrogation of galectin-4 expression promotes cancer cell proliferation and, for the first time, provide evidence that down-regulation of galectin-4 elicits tumor promotion in vitro and in vivo through activation of IL-6/NF-κB/STAT3 signaling.",
author = "Kim, {Seung Won} and Park, {Ki Cheong} and Jeon, {Soung Min} and Ohn, {Tak Bum} and Kim, {Tae Il} and Kim, {Won Ho} and Cheon, {Jae Hee}",
year = "2013",
month = "4",
day = "1",
doi = "10.1007/s13402-013-0124-x",
language = "English",
volume = "36",
pages = "169--178",
journal = "Cellular oncology (Dordrecht)",
issn = "2211-3428",
publisher = "Springer Netherlands",
number = "2",

}

Abrogation of galectin-4 expression promotes tumorigenesis in colorectal cancer. / Kim, Seung Won; Park, Ki Cheong; Jeon, Soung Min; Ohn, Tak Bum; Kim, Tae Il; Kim, Won Ho; Cheon, Jae Hee.

In: Cellular Oncology, Vol. 36, No. 2, 01.04.2013, p. 169-178.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Abrogation of galectin-4 expression promotes tumorigenesis in colorectal cancer

AU - Kim, Seung Won

AU - Park, Ki Cheong

AU - Jeon, Soung Min

AU - Ohn, Tak Bum

AU - Kim, Tae Il

AU - Kim, Won Ho

AU - Cheon, Jae Hee

PY - 2013/4/1

Y1 - 2013/4/1

N2 - Background: Although it has been well established that galectin-4 is selectively expressed by intestinal epithelial cells, the role of galectin-4 in colorectal cancer (CRC) development is, as yet, poorly understood. Here, we aimed to explore the role of galectin-4 in CRC development, both in vitro and in vivo. Methods: Galectin-4 expression was investigated in tissue specimens from patients with adenoma, carcinoma and ulcerative colitis (UC) using immunohistochemistry. Colorectal cancer-derived HT-29 cells, in which galectin-4 expression was knocked down, were established using shRNA. mRNA and protein expression levels of galectin-4 and several downstream cancer-related genes were analyzed using RT-PCR, qPCR array, Western blotting, and immunofluorescence assays. To investigate the effect of galectin-4 expression abrogation on tumorigenesis in vivo, xenograft assays were performed. Results: Immunohistochemistry analyses showed high expression levels of galectin-4 in normal colon mucosa tissues. Conversely, the expression levels of galectin-4 were significantly lower in CRC samples and its precursor lesions with dysplasia or inflammation. We found that shRNA-mediated galectin-4 silencing increases cell proliferation and, concomitantly, activates NF-κB and STAT3 signaling along with IL-6 up-regulation. In addition, we found that shRNA-mediated galectin-4 silencing promotes the expression of NF-κB target genes and other cancer-related genes and, concomitantly, enhances the in vivo growth of xenografts. Conclusions: We show that abrogation of galectin-4 expression promotes cancer cell proliferation and, for the first time, provide evidence that down-regulation of galectin-4 elicits tumor promotion in vitro and in vivo through activation of IL-6/NF-κB/STAT3 signaling.

AB - Background: Although it has been well established that galectin-4 is selectively expressed by intestinal epithelial cells, the role of galectin-4 in colorectal cancer (CRC) development is, as yet, poorly understood. Here, we aimed to explore the role of galectin-4 in CRC development, both in vitro and in vivo. Methods: Galectin-4 expression was investigated in tissue specimens from patients with adenoma, carcinoma and ulcerative colitis (UC) using immunohistochemistry. Colorectal cancer-derived HT-29 cells, in which galectin-4 expression was knocked down, were established using shRNA. mRNA and protein expression levels of galectin-4 and several downstream cancer-related genes were analyzed using RT-PCR, qPCR array, Western blotting, and immunofluorescence assays. To investigate the effect of galectin-4 expression abrogation on tumorigenesis in vivo, xenograft assays were performed. Results: Immunohistochemistry analyses showed high expression levels of galectin-4 in normal colon mucosa tissues. Conversely, the expression levels of galectin-4 were significantly lower in CRC samples and its precursor lesions with dysplasia or inflammation. We found that shRNA-mediated galectin-4 silencing increases cell proliferation and, concomitantly, activates NF-κB and STAT3 signaling along with IL-6 up-regulation. In addition, we found that shRNA-mediated galectin-4 silencing promotes the expression of NF-κB target genes and other cancer-related genes and, concomitantly, enhances the in vivo growth of xenografts. Conclusions: We show that abrogation of galectin-4 expression promotes cancer cell proliferation and, for the first time, provide evidence that down-regulation of galectin-4 elicits tumor promotion in vitro and in vivo through activation of IL-6/NF-κB/STAT3 signaling.

UR - http://www.scopus.com/inward/record.url?scp=84876495130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876495130&partnerID=8YFLogxK

U2 - 10.1007/s13402-013-0124-x

DO - 10.1007/s13402-013-0124-x

M3 - Article

C2 - 23378274

AN - SCOPUS:84876495130

VL - 36

SP - 169

EP - 178

JO - Cellular oncology (Dordrecht)

JF - Cellular oncology (Dordrecht)

SN - 2211-3428

IS - 2

ER -